[go: up one dir, main page]

DK0597033T3 - IGF-1 til forbedring af den neurale tilstand - Google Patents

IGF-1 til forbedring af den neurale tilstand

Info

Publication number
DK0597033T3
DK0597033T3 DK92917908.3T DK92917908T DK0597033T3 DK 0597033 T3 DK0597033 T3 DK 0597033T3 DK 92917908 T DK92917908 T DK 92917908T DK 0597033 T3 DK0597033 T3 DK 0597033T3
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
igf
improve
analogues
Prior art date
Application number
DK92917908.3T
Other languages
Danish (da)
English (en)
Inventor
Peter Gluckman
Karoly Nikolics
Original Assignee
Genentech Inc
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19923685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0597033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Auckland Uniservices Ltd filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0597033T3 publication Critical patent/DK0597033T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Color Image Communication Systems (AREA)
DK92917908.3T 1991-08-01 1992-08-03 IGF-1 til forbedring af den neurale tilstand DK0597033T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ23921191 1991-08-01

Publications (1)

Publication Number Publication Date
DK0597033T3 true DK0597033T3 (da) 1997-06-02

Family

ID=19923685

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92917908.3T DK0597033T3 (da) 1991-08-01 1992-08-03 IGF-1 til forbedring af den neurale tilstand

Country Status (9)

Country Link
US (2) US5714460A (fr)
EP (1) EP0597033B1 (fr)
AT (1) ATE151293T1 (fr)
CA (1) CA2114251C (fr)
DE (1) DE69218948T2 (fr)
DK (1) DK0597033T3 (fr)
ES (1) ES2101865T3 (fr)
GR (1) GR3023874T3 (fr)
WO (1) WO1993002695A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
EP0729361A4 (fr) * 1993-11-15 1996-11-06 Celtrix Pharma Procede de traitement de troubles neurologiques
EP0735894A4 (fr) 1993-12-23 1999-08-18 Auckland Uniservices Ltd Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5656605A (en) * 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5965531A (en) * 1995-08-31 1999-10-12 National Institutes Of Health Method of reducing perivascular lesions using insulin-like growth factor I
ES2196194T3 (es) * 1995-12-13 2003-12-16 Aurogen Inc Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central.
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
WO1999020299A1 (fr) * 1997-10-17 1999-04-29 Spencer E Martin Incontinence urinaire chez l'homme et procedes de traitement
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
CN1305383A (zh) * 1998-06-15 2001-07-25 诺兰兹公司 酪氨酸羟化酶的调节
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
IL143866A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
WO2001037855A2 (fr) * 1999-10-27 2001-05-31 Chiron Corporation Sauvetage neuronal fonction de la temperature
WO2002017951A1 (fr) * 2000-08-29 2002-03-07 Colorado State University Research Foundation Methode de traitement du systeme nerveux central par administration d'analogues structuraux d'igf
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
ATE349469T1 (de) * 2001-02-09 2007-01-15 Genentech Inc Kristallisierung von igf-1
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
WO2002094856A2 (fr) 2001-05-24 2002-11-28 Neuronz Limited Peptidomimetiques et analogues de gpe
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
WO2003025121A2 (fr) * 2001-09-18 2003-03-27 Bioexpertise, Llc Peptide ou petite molecule derive de proteines de liaison de l'igf
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US7192738B2 (en) * 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
WO2006097682A1 (fr) * 2005-03-18 2006-09-21 Ucl Business Plc Peptides du facteur de mecano-croissance et leur utilisation
JP2009533458A (ja) * 2006-04-14 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー 神経系の可塑性を媒介する分子経路の同定および変調
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US8552158B2 (en) 2006-08-31 2013-10-08 Hoffmann-La Roche Inc. Method for the production of insulin-like growth factor-1
JP2010529128A (ja) * 2007-06-08 2010-08-26 マサチューセッツ インスティテュート オブ テクノロジー レット症候群および他の障害の処置
CA2720478A1 (fr) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Test de facteur de croissance analogue a l'insuline pegyle
WO2009121759A2 (fr) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Utilisation de variants de igf-i pegylés pour traiter des troubles neuromusculaires
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
WO2016184427A1 (fr) * 2015-05-21 2016-11-24 中国科学院上海生命科学研究院 Cellule souche mésenchymateuse cultivée en hypoxie et utilisation de celle-ci
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
BR112020023252A2 (pt) 2018-05-15 2021-02-23 Lloyd Hung Loi Tran composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos.
WO2021005604A1 (fr) 2019-07-11 2021-01-14 Opko Biologics Ltd. Igf-1 ou variants d'igf-1 à action prolongée et procédés de production associés
AU2020346186A1 (en) 2019-09-09 2022-04-07 Seurat Therapeutics Combination therapy for the treatment of migraines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5817623A (en) 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
WO1991002067A1 (fr) * 1989-07-27 1991-02-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation de la synthese du facteur de croissance nerveuse dans le systeme nerveux central
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US20070078089A1 (en) 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II

Also Published As

Publication number Publication date
GR3023874T3 (en) 1997-09-30
ES2101865T3 (es) 1997-07-16
USRE43982E1 (en) 2013-02-05
US5714460A (en) 1998-02-03
WO1993002695A1 (fr) 1993-02-18
DE69218948T2 (de) 1997-07-31
EP0597033B1 (fr) 1997-04-09
EP0597033A1 (fr) 1994-05-18
ATE151293T1 (de) 1997-04-15
CA2114251C (fr) 2007-11-06
CA2114251A1 (fr) 1993-02-18
DE69218948D1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
DK0597033T3 (da) IGF-1 til forbedring af den neurale tilstand
CA2122058A1 (fr) Amelioration du developpement neuronal par le tgf-beta
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP1234586A3 (fr) Agents hépatosélectifs à activité pharmaceutique
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
GB9519661D0 (en) Fatty acid treatment
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
WO1994008551A3 (fr) Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume
MY131805A (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
ZA911496B (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
CA2108330A1 (fr) Stimulateur de l'effet anti-anemique de l'erythropoietine et methode d'augmentation de cet effet
EP0515434A4 (en) Method for treating intestinal diseases
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
RU93050675A (ru) Способ коррекции психофизиологического состояния человека
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
SG49645A1 (en) A method of treating liver disease and like indications with vasodilating agents
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients